Investigational Drug
NXP900
TrialFetch AI Analysis
Show TrialFetch AI Analysis
Overview
NXP900 (eCF506) is an investigational oral cancer drug being studied in people with advanced solid tumors. A first-in-human phase 1 study has reported safety and laboratory measures of drug activity; those findings do not establish that NXP900 shrinks tumors or improves patient outcomes. (aacrjournals.org)
Mechanism of action
NXP900 inhibits SRC-family kinases, particularly YES1 and SRC. It holds the kinases in an inactive, “closed” shape, blocking both their enzymatic activity and interactions with signaling partners. In the phase 1 study, researchers observed reduced SRC phosphorylation in patients’ blood cells—a measure of target activity, not clinical benefit. (aacrjournals.org)
Efficacy
No clinical response rate has been reported in the published phase 1 abstract. Its results cover 26 patients treated with 20–200 mg daily but do not report tumor responses or survival outcomes. Antitumor findings reported in cell and animal studies cannot establish efficacy in people. (aacrjournals.org)
Safety
Among the 26 patients, the most commonly reported treatment-emergent adverse events were fatigue (42%), diarrhea (35%), nausea (31%), and shortness of breath (23%). Most events in these categories were grade 1 or 2. These are early, small-study findings; “treatment-emergent” does not mean every event was caused by NXP900. (aacrjournals.org)
Further reading
- First-in-human phase 1 results (AACR abstract)
- Mechanism and preclinical research (Cancer Research)
- Phase 1 study record (ClinicalTrials.gov)
Last updated: Sep 2026
Active trials using NXP900
Found 3 active trials using this drug:
TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic ALK-positive NSCLC who have received and tolerated lorlatinib are treated with lorlatinib plus escalating doses of NXP900, an oral SRC-family kinase inhibitor targeting YES1 and SRC. The study particularly addresses disease progression or acquired resistance during lorlatinib treatment.
ClinicalTrials.gov ID: NCT07784959
TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic EGFR-mutated NSCLC that has progressed after first- or second-line osimertinib receive escalating doses of NXP900 plus osimertinib. NXP900 is an investigational oral inhibitor of SRC-family kinases, particularly YES1 and SRC.
ClinicalTrials.gov ID: NCT07315113
TrialFetch AI summary: Adults with advanced solid tumors and ECOG 0–1 receive once-daily oral NXP900, a SRC-family kinase inhibitor targeting YES1 and SRC. Dose escalation enrolls patients without an appropriate available therapy; dose expansion enrolls patients with selected molecular alterations after 1–3 prior therapies.
ClinicalTrials.gov ID: NCT05873686
